Red Flags Detected

  • Going Concern (unchanged) — Substantial doubt about ability to continue as going concern persists despite extended cash runway to Q1 2027.
  • Related Party (new) — Completed acquisition of related-party entity SKNY Pharmaceuticals, now reporting equity method losses of $92K in Q1 2026.
NASDAQ: MIRA MIRA PHARMACEUTICALS, INC. 10-Q

MIRA completes SKNY acquisition, advances Ketamir-2 to Phase 2a prep, extends cash to Q1 2027

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

Key Changes

  • high

    Ketamir-2 Phase 1 dosing completed across all cohorts with no serious adverse events or dose-limiting toxicities; Phase 2a trial in chemotherapy-induced neuropathy planned for H1 2026.

    MD&A: Clinical Development verify on EDGAR →
  • high

    Completed acquisition of related-party SKNY Pharmaceuticals (Sept 2025), adding SKNY-1 weight management/addiction candidate to pipeline; company now reports equity method investment losses.

    MD&A: Acquisitions verify on EDGAR →
  • high

    Cash runway extended to Q1 2027 (from Q4 2025 baseline) with $4.8M on hand, though going concern warning persists; Nasdaq equity deficiency notice from April 2025 no longer mentioned.

    MD&A: Liquidity verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade MIRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 10, 2026 9:16 PM